Compounded GLP-1 ban in Australia

What happened?

Before the ban, some Australian compounding pharmacies produced their own versions of semaglutide at a fraction of the cost of brand-name products. These compounded versions were popular because they could cost as little as $100–150/month compared to $400+ for Wegovy.

However, compounded medications are not subject to the same quality controls, testing, or regulatory oversight as TGA-approved products. The TGA moved to ban them after concerns emerged about:

• Contamination risks: No standardised manufacturing environment
• Inconsistent dosing: Patients potentially receiving too much or too little medication
• Lack of quality assurance: No batch testing or stability data
• Adverse events: Reports linked to compounded GLP-1 products
• Lack of clinical evidence: No trials demonstrating safety or efficacy of compounded versions

Is the ban permanent?

The TGA has given no indication the ban will be reversed. As more TGA-approved options become available (and potentially PBS-subsidised), the rationale for compounded versions weakens further.

What are your options now?

Only TGA-approved medications from licensed manufacturers:

If cost is the barrier

The most common reason people used compounded GLP-1s was cost. Here are legitimate ways to reduce your medication costs:

• Cheapest weight loss medication options →
• Check PBS eligibility (Wegovy listing pending) →
• Cheapest telehealth providers →
• Consider Duromine (~$100/month) as a short-term option